Down‐regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity

Y Zeng, P Kulkarni, T Inoue… - Journal of cellular …, 2009 - Wiley Online Library
Y Zeng, P Kulkarni, T Inoue, RH Getzenberg
Journal of cellular biochemistry, 2009Wiley Online Library
The microenvironment of the cancer cell is pivotal to its phenotypic regulation. One of the
central components of the microenvironment is temperature. An elevation in environmental
temperature has been shown to increase the cancer cell's susceptibility to chemo‐and
radiation therapy. The goal of the studies described here was to identify some of the
pathways that are modified by a mild increase in temperature in cancer cells. Using prostate
cancer cells as a model system we found that in addition to the well described and …
Abstract
The microenvironment of the cancer cell is pivotal to its phenotypic regulation. One of the central components of the microenvironment is temperature. An elevation in environmental temperature has been shown to increase the cancer cell's susceptibility to chemo‐ and radiation therapy. The goal of the studies described here was to identify some of the pathways that are modified by a mild increase in temperature in cancer cells. Using prostate cancer cells as a model system we found that in addition to the well described and anticipated up‐regulation of the heat shock family of proteins, there is a significant down‐regulation of certain members of the “cold shock” family of proteins such as, RNA binding motif protein 3 (RBM3) and cold inducible RNA binding protein (CIRBP). siRNA‐mediated down‐regulation of the cold shock protein (CSP) encoding mRNAs dramatically attenuates cell survival in the absence of any heat application. Furthermore, we also demonstrate that knocking down the CSPs can enhance the therapeutic response of prostate cancer cells to chemotherapy. Our findings suggest that down‐regulating CSPs in cancer cells may “mimic” the stress response the cells experience when exposed to heat treatment rendering them more susceptible to therapy. Thus, the pharmacological modulation of RBM3 and CIRBP may represent novel therapeutic approaches for prostate cancer. J. Cell. Biochem. 107: 179–188, 2009. © 2009 Wiley‐Liss, Inc.
Wiley Online Library